MAGEA3

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MAGEA3
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
AliasesMAGEA3, CT1.3, HIP8, HYPD, MAGE3, MAGEA6, MAGE family member A3
External IDsOMIM: 300174 HomoloGene: 55892 GeneCards: MAGEA3
Gene location (Human)
X chromosome (human)
Chr.X chromosome (human)[1]
X chromosome (human)
Genomic location for MAGEA3
Genomic location for MAGEA3
BandXq28Start152,698,767 bp[1]
End152,702,347 bp[1]
RNA expression pattern
PBB GE MAGEA3 209942 x at fs.png

PBB GE MAGEA3 214612 x at fs.png
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_005362

n/a

RefSeq (protein)

NP_005353

n/a

Location (UCSC)Chr X: 152.7 – 152.7 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Melanoma-associated antigen 3 (MAGE-A3) is a protein that in humans is encoded by the MAGEA3 gene.[3][4][5]

Genetics[edit]

This gene is a member of the melanoma-associated antigen gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.[5]

Function and Clinical relevance[edit]

The normal function of MAGE-A3 in healthy cells is unknown.[6] The presence of the antigen on tumor cells has been associated with worse prognosis. In one study, high levels of MAGE-A3 in lung adenocarcinoma were associated with shorter survival.[7]

MAGE-A3 is a tumor-specific protein, and has been identified on many tumors including melanoma, non-small cell lung cancer, hematologic malignancies, among others.[8] Currently, GlaxoSmithKline is developing a cancer vaccine targeting MAGE-A3. The vaccine is a fusion protein of MAGE-A3 and Haemophilus influenzae protein D, combined with a proprietary immunoadjuvant.[9]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000221867 - Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (Jan 1992). "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma". Science. 254 (5038): 1643–7. doi:10.1126/science.1840703. PMID 1840703.
  4. ^ Rogner UC, Wilke K, Steck E, Korn B, Poustka A (Mar 1996). "The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28". Genomics. 29 (3): 725–31. doi:10.1006/geno.1995.9945. PMID 8575766.
  5. ^ a b "Entrez Gene: MAGEA3 melanoma antigen family A, 3".
  6. ^ Decoster L, Wauters I, Vansteenkiste JF (Dec 2011). "Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development". Annals of Oncology. 23 (6): 1387–1393. doi:10.1093/annonc/mdr564. PMID 22156658.
  7. ^ Ali O. Gure; Ramon Chua; Barbara Williamson; Mithat Gonen; Cathy A. Ferrera; Sacha Gnjatic; Gerd Ritter; Andrew J.G. Simpson; Yao-T. Chen; Lloyd J. Old; Nasser K. Altorki (Nov 2005). "Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer". Clinical Cancer Research. 11 (22): 8055–8062. doi:10.1158/1078-0432.CCR-05-1203. PMID 16299236.
  8. ^ Corporate Comms. "New data on MAGE-A3 cancer immunotherapy support potential novel options of treating non-small cell lung cancer and melanoma". Us.gsk.com. Archived from the original on 2012-06-27. Retrieved 2012-10-16.
  9. ^ "Patent US20100008980 - Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with ... - Google Patents". 2008-01-08. Retrieved 2012-10-16.

Further reading[edit]